Monitor for updated Phase 1 clinical data in H2 2026, which could validate efficacy and safety in humans. The absence of hyperglycemia and strong preclinical combination data may support premium valuation if clinical results align.
Price Chart
Executive Summary
BBOT presented new preclinical data for BBO-10203, a first-in-class RAS:PI3Kα breaker, showing tumor regressions and strong combination effects with HER2 inhibitors in HER2AMP models, with no observed hyperglycemia. Updated clinical data are expected in the second half of 2026.
Key Facts
- BBO-10203 disrupts RAS and PI3Kα interaction, inhibiting RAS-driven PI3Kα-AKT signaling without inhibiting PI3Kα kinase activity.
- No hyperglycemia observed at 100 mg/kg QD, a potential safety advantage over competing therapies.
- BBO-10203 shows strong in vivo combination effects with tucatinib and trastuzumab in HER2AMP models.
- Phase 1 BREAKER-101 trial is ongoing; updated clinical data expected in second half of 2026.
- Mechanism is agnostic to RAS or PI3Kα mutational status, potentially broadening eligible patient population.
Financial Impact
No immediate financial impact; potential long-term value from clinical advancement and expanded indications.
Risk Factors
- Clinical trial results may not replicate preclinical findings.
- Regulatory delays or safety signals in ongoing BREAKER-101 trial.
- Competition from other RAS or PI3K-targeted therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | EFFECT | $4.95 $3.31 | ▲ +33.13% | ▲ +35.00% | $2.64 (+46.67%) |
Sep 9, 2026 6w ago | EFFECT | $6.76 $3.44 | ▼ −49.07% | ▼ −51.27% | $2.64 (−60.92%) |
Aug 15, 2026 10w ago | Institutional Cluster | $9.04 $4.88 | ▲ +46.02% | ▲ +44.04% | $2.64 (+70.80%) |
Aug 11, 2026 10w ago | Press Release | $9.42 $5.52 | ▼ −41.40% | ▼ −39.50% | $2.64 (−71.97%) |
Jun 22, 2026 17w ago | 8-K | $7.50 $8.42 | ▲ +12.27% | ▲ +11.11% | $2.64 (−64.80%) |
May 12, 2026 23w ago | Press Release | $8.08 $7.46 | ▼ −7.67% | ▼ −7.06% | $2.64 (−67.33%) |
Apr 21, 2026 26w ago | Press Release | $8.87 $8.72 | ▼ −1.69% | ▼ −4.86% | $2.64 (−70.24%) |
Apr 20, 2026 26w ago | Press Release | $9.46 $8.75 | ▼ −7.51% | ▼ −12.42% | $2.64 (−72.09%) |
Mar 6, 2026 33w ago | Press Release | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.64 (−74.66%) |
Mar 5, 2026 33w ago | 8-K | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.64 (−74.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers